WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.